List of Contributors
Eliana Abdelhay(Instituto Nacional de Câncer - INCA), Farhadul Islam(Griffith University), Véronique Hofman(Centre National de la Recherche Scientifique), Massimo Di Maïo(University of Siena), Simon Heeke(The University of Texas MD Anderson Cancer Center), Vera Cappelletti(Fondazione IRCCS Istituto Nazionale dei Tumori), Geraldine O’Sullivan Coyne(National Institutes of Health), Anne Margreet Sofie Berghuis(University of Twente), Paolo Grassi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), Rosalba De Nola, Marius Ilié(University Health Network), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stella D’Oronzo(Libera Università Maria SS. Assunta), Massimo Cristofanilli(Cornell University), Pavan P. Adiseshaiah(Johns Hopkins University), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Mauro Cives(University of Bari Aldo Moro), Francesca Fenizia, Alice P. Chen(National Institutes of Health), Giovanni Grignani(Candiolo Cancer Institute), Lorenzo D’Ambrosio(Ospedale San Luigi Gonzaga), Vikas Ghai, Franco Dammacco(University of Bari Aldo Moro), Paola Ferrari(Sapienza University of Rome), Massimo Aglietta(Verizon (United States)), Janet E. Brown(University of Sheffield), Mario Giuliano(Regione Campania), Guido Biasco(University of Bologna), Amélie Dendooven(University of Antwerp), Vinod Gopalan(Griffith University), Nuria Coll Bastus(Queen Mary University of London), Stephany Corrêa, Gennaro Daniele(Università Cattolica del Sacro Cuore), Maryline Allégra(Centre Hospitalier Universitaire de Nice), Sock Hoai Chan, Nicoletta Chicchinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Vittoria Dieci(Istituto Oncologico Veneto), Alessia Iannaccone, Renata Binato(Instituto Nacional de Câncer - INCA), Tanja Fehm(Düsseldorf University Hospital), Paul Hofman(Inserm), Maxime Chénard-Poirier(Université Laval), Ahmed Basudan(King Saud University), Raffaele Costanzo, Ru Chen(University of Washington), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ankita Borah(University of Strathclyde), Rekha Gyanchandani
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k